Barclays
ELTX icon

Barclays’s Elicio Therapeutics ELTX Stock Holding History

Barclays’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.94K Buy
+1,776
New +$17.8K ﹤0.01% 4745
2023
Q2 		– Sell
-362
Closed -$2.1K – 4679
2023
Q1 		$2.1K Hold
362
– – ﹤0.01% 4887
2022
Q4 		$2.94K Hold
362
– – ﹤0.01% 5057
2022
Q3 		$3K Hold
362
– – ﹤0.01% 4576
2022
Q2 		$4K Sell
362
-353
-49% -$5.64K ﹤0.01% 4811
2022
Q1 		$15K Buy
+715
New +$16.1K ﹤0.01% 4516

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Barclays's ELTX Position: Q2 2026 in Review

Barclays opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 1,776 shares worth $6.94K. The stake represents ﹤0.01% of the portfolio and ranks #4745 among its holdings. This is a return to the name: Barclays previously reported a position in ELTX as recently as Q1 2023.

Barclays first reported a position in ELTX in Q1 2022 and has held it in 6 quarters since. The position peaked at $15K in Q1 2022. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Barclays held 1,776 shares of Elicio Therapeutics worth $6.94K as of Q2 2026.
  • Elicio Therapeutics was a new Barclays position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4745 holding.
  • Barclays first reported a position in Elicio Therapeutics in Q1 2022 and has held it in 6 quarters since.
  • Barclays's Elicio Therapeutics position peaked at $15K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.